THERMO FISHER SCIENTIFIC TO ACQUIRE PATHEON, A LEADING CONTRACT
15 May 2017 Articles
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash.
Morrow Sodali is serving as the proxy solicitor for Patheon N.V.
Related News
Sodali & Co Debt Team supports Ukraine to achieve budget liquidity and financial stability
12 September 2024
Banco Sabadell to file a complaint with the Spanish National Securities Market Commission (CNMV) alleging that BBVA violated takeover regulations
10 May 2024
Morrow Sodali Names Barri Rafferty as CEO of the Americas
05 September 2023
Morrow Sodali proud to play a key role in Ukraine's successful debt deferral
04 October 2022
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right